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Abstract: Carbamazepine (CBZ) is a widely used antiepileptic drug. It is used to control grandmal seizure as well as in the treatment
of neuralgia. The drug is characterised by slow and irregular gastrointestinal absorption due to its low water solubility. In clinics,
for conventional dosage forms of CBZ, single daily dosing is insufficient; effective CBZ level is provided by multiple drug
administration. Multiplicity of dosage causes inconsistent plasma CBZ levels leading to side effects because of narrow therapeutic
and toxic levels.
In this study, quality controls of different conventional CBZ tablets which are commercially available on the Turkish drug market
were examined. Quality control parameters were weight variations, diameter and thickness, content uniformity, friability and
dissolution tests. Differences between conventional CBZ tablets were evaluated.
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Introduction
In the drug industry, quality control must be
administered in order to prevent the kind of product
which is not suitable for the aim, and at the same time it
is also necessary for controlling the reliability of the
production process. Quality can be defined as the
suitability of the goods or service to the determined
qualifications. In the establishment of quality control
programmes the aim is to guarantee the determined
necessities (1).
Carbamazepine (CBZ) is a widely used antiepileptic
drug. It is used to control grandmal seizure as well as in
the treatment of neuralgia. The drug is characterised by
slow and irregular gastrointestinal absorption due to its
low water solubility (2). A single daily dose of CBZ is
insufficient; 2 doses per day are appropriate in most
cases, but some patients may benefit from more frequent
dosing to avoid side-effects (3).
In clinical studies, suspension, conventional tablets and
XR (extended release) tablets delivered equivalent
amounts of drug to the systemic circulation. However,

the suspension was absorbed somewhat more rapidly and
XR tablet slightly slower than the conventional tablet.
Bioavailability of the XR tablet was 89% compared to the
suspension. Following a twice daily dosage regimen, the
suspension provides higher peak levels and lower trough
levels than those obtained from the conventional tablet
for the same dosage regimen. On following a three times
daily dosage regimen, CBZ suspension affords steadystate plasma levels comparable to CBZ tablets given b.i.d
when administered at the same total mg daily dose (4).
On Turkish drug market, there are conventional and
controlled release of CBZ in the forms of tablets and
syrups produced by different companies (5).
In this study, we worked on the quality controls of
conventional CBZ tablets which are available in the Turkish
drug market. For quality controls, weight variation,
diameter and thickness, content uniformity, hardness,
friability and dissolution tests were administered.
Furthermore, difference (ƒ1) and similarity (ƒ2) tests were
applied to these tablets so as to evaluate the differences
and similarities of their dissolution profiles.
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Materials and Method
Materials
Carbamazepine was a kind gift of Novartis
Pharmaceuticals, Turkey. In our studies, four brands of
commercial conventional CBZ tablets containing 200 mg
of CBZ were used and coded as CBZ A (Lot:043), CBZ B
(Lot:01), CBZ C (Lot:041) and CBZ D (Lot:05).
Method
Analytical method for the assay of carbamazepine
In order to determine the standard calibration curve
of CBZ, a stock solution of 0.016 mg/ml was prepared in
distilled water containing 1% sodium lauryl sulphate
(NaLS). Then dilutions were made to prepare a series of
solutions containing CBZ in different concentrations. In
these solutions absorbance values at 287 nm (maximum
λ) were determined UV spectrophotometrically by
plotting the concentration values (x) versus absorbances
(y) a calibration curve of CBZ in distilled water containing
1% NaLS was determined (6). Analytical parameters for
the assay of CBZ were calculated by the ANOVA test.
LOD and LOQ determination
The limit of detection (LOD) and the limit of
quantitation (LOQ) were determined by using the
following equations;
LOD = 3SD/m (Equation 1)
LOQ = 10SD/m (Equation 2)
where SD is the standard deviation of the absorbance
values (n=6) of the second smallest concentration, m is
the slope of the calibration curve (6).
Evaluated physical characteristics for quality
control studies
Weight variation: Each tablet (n=10) belonging to
each brand was weighed with an electronic balance
(Sartorius BL 210 S) (1).

Content uniformity test: The amount of CBZ in
tablets from each brand was determined according to
USP 28. A standard solution was prepared by dissolving
pure CBZ in methanol and a sample solution was also
prepared dissolving CBZ tablets (n = 20) from each batch
in methanol. The absorbances of the prepared solutions
were determined spectrophotometrically at 287 nm
(Shimadzu 1202 UV-VIS spectrophotometer). The CBZ
amount in each tablet was calculated using the equation
for the calibration curve.
Dissolution studies: The dissolution rate studies on
conventional CBZ tablets were carried out according to
USP 28 paddle method at a stirring rate of 75 rpm. The
dissolution medium was 900 ml of distilled water
°
containing 1%NaLS at 37 ± 0.5 C. The samples were
withdrawn at definite time intervals for one hour and
assayed spectrophotometrically at
287
nm
(Shimadzu
1202
UV-VIS
spectrophotometer). The percentage of cumulative CBZ
amounts released from the tablets were calculated. Then
data were plotted and evaluated using a statistical
package program (SPSS 9.0).
Comparison of the dissolution profiles
In this study, as model-independent approaches, two
fit factors that compare the dissolution profiles of a pair
of drug products were applied to the dissolution data.
These fit factors directly compare the difference between
percent drug dissolved per unit time for a test and a
reference product. The fit factors are denoted difference
(ƒ1) and similarity (ƒ2) factors and are defined by
equations 3 and 4 (8),
n

fl =

Friability test: 10 tablets from each brand were
weighed and put into the friabilitor (Roche Friabilitor).
Tablets were rotated at 25 rpm, then the friability
percentage was calculated for each batch (7).
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Measurement of diameter and thickness: The
diameter and thickness of CBZ tablets (n=10) from each
brand were measured with a micrometer (Zeus) (1).
Hardness test: This test was applied with a hardness
tester (Strong-Cobb T 100 tablet hardness tester) on 10
tablets for each brand (1).
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X100 (Equation 4)

where n is the number of dissolution sample times and Rt
and Tt are the individual or mean percents dissolved at
each time point, t, for the reference and test dissolution
profiles respectively.
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Table 1. Analytical method validation parameters for the assay of
carbamazepine by UV spectrophotometric method.

Results and Discussion
Results of assay of carbamazepine
The calibration curve of CBZ was obtained by using
the method which was explained in section 1.2.1 and the
calibration curve was shown in Figure 1. Analytical
method validation parameters for the determination of
CBZ by UV spectrophotometric method were given in
Table 1.
Quality control study results
The results obtained from the quality control tests
were given in Table 2.
Carbamazepine tablets contain not less than 92.0
percent and not more than 108.0 percent of the labeled
amount of active drug (9). Content uniformity test results
showed that all conventional CBZ tablets fit this criteria
(Table 2).
Although there is no official test for hardness, this
property must be controlled to ensure that the product is
firm enough to withstand handling without breaking or
crumbling and not so hard that the disintegration time is
unduly prolonged (7). The recommended value for tablet
hardness is 4-8 kg (7). All tablets supply the hardness
limits.
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Figure 1. Calibration curve for carbamazepine.

Parameter

Result

Linearity range (mg/ml)

0.032 - 0.40

Slope (m)

1.8561

RSD of m (%)

0.81

SE of m

0.048

CL of m (95%)

1.7491-1.9962

Intercept (n)

-0.0187

RSD of n (%)

6.24

SE of n

0.009

CL of n (95%)

-0.0381-0.0012

Determination coefficent (r2)

0.994

LOD (mg/ml)

0.034

LOQ (mg/ml)

0.114

RSD for precision (%)

69.79

RSD for accuracy

4.314

RSD: Relative Standard Deviation
SE: Standard Error
CL: Confidence Limits

The friability value which is also affected by the
hardness value of tablets, should be in the range of 0.51% limits (7). Friability values of the tablets are in this
range.
Difference (ƒ1) and similarity (ƒ2) tests were applied
to the dissolution data. The difference (ƒ1) factor is
proportional to the average difference between the two
profiles, whereas similarity (ƒ2) factor is inversely
proportional to the average squared difference between
the two profiles with emphasis on the larger difference
among all the time points (8). The use of these factors
was also recommended for dissolution profile comparison

Table 2. Results of quality control tests.
CBZ Tablet

Weight (g)
(X mean±SD)

Diameter
(cm)

Thickness
(cm)

Hardness
(SCU ± SD)

Friability
(%)

Content
uniformity (%)

CBZ A

0.280 ± 0.002

0.905

0.365

18.75 ± 2.93

0.76

105.7

CBZ B

0.399 ± 0.006

1.050

0.390

13.10 ± 3.13

0.61

101.3

CBZ C

0.402 ± 0.003

1.150

0.360

13.00 ± 1.16

0.82

104.9

CBZ D

0.258 ± 0.005

0.955

0.305

12.65 ± 2.84

0.64

98.4

SCU: Strong Cobb Unit (1 SCU = 0.643 kg)
SD: Standard Deviation
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Table 3. Difference (ƒ1) and similarity (ƒ2) factors for reference (CBZ
A) versus test products (CBZ B, C and D).
CBZ B

CBZ C

CBZ D

ƒ1 values

7.36

12.24

44.12

ƒ2 values

57.47

51.72

22.17

in the FDA guide for industry (10). According to these
guides, generally ƒ1 values vary between 0-15 and ƒ2
values vary between 50-100, and ensures sameness or
equivalance of the curves.
The values of ƒ1and ƒ2 factors for test products versus
reference were calculated from the means of percent
dissolved at each time point by using Equations 3 and 4
and listed in
Table 3. For tests (CBZ B and CBZ C)) versus
reference (CBZ A), ƒ1 values indicate that the dissolution
profiles of tests (CBZ B and CBZ C) were similar to the
profile of reference

Drug Released %
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Figure 2. Dissolution profiles of conventional carmabamazepine tablets.

To release the active amount in an expected time is
the primary effect of a dosage form. According to USP
28, conventional CBZ tablets have to release at least 75%
of the labelled amount in 60 minutes. As can be seen in
Figure 2, except for CBZ D, all other CBZ conventional
tablets release the active drug according to the
determined limits.
Dissolution data of conventional CBZ tablets were
applied to zero order, first order, and Higuchi and
Hixson-Crowell kinetics (Table 4). As seen from Table 4,

Table 4. Kinetic parameters obtained from the dissolution data for conventional CBZ tablets.
CBZ Tablet
CBZ A

CBZ B

CBZ C

CBZ D

Kinetic model
First order

RMS
k1
r2

6.674
0.838
0.703

6.140
0.846
0.715

5.529
0.857
0.735

3.981
0.871
0.759

Zero order

RMS
k0
r2

1375.810
0.892
0.795

970.755
0.914
0.835

700.398
0.936
0.875

179.929
0.960
0.922

Hixson-Crowell

RMS
k4
r2

5.301
0.846
0.796

4.725
0.856
0.733

4.148
0.870
0.757

2.781
0.882
0.778

Higuchi

RMS
k
r2

301.560
0.997
0.955

150.249
0.987
0.974

67.197
0.994
0.988

2.054
1.00
0.999

RMS: Residual Mean Square
k: Rate constant of the investigated kinetic
r2 : Determination coefficent
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Higuchi kinetics gives the highest determination constant
and shows the best suitability for all dissolution data. CBZ
D (Lot: 05) does not fit the USP 28 criteria (a
conventional CBZ tablet should release at least 75% of
the labelled amount in 60 minutes).

Tansel ÇOMO⁄LU
Department of Pharmaceutical Technology,
Faculty of Pharmacy,
Ankara University,

In conclusion, it can be said that, except for CBZ D
(Lot:05), conventional CBZ tablets available on the
Turkish drug market, fulfill the USP 28 pharmacopeia
standards.

06100 Tando¤an, Ankara - Turkey
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